$2.07
0.000.00%
At close: -
$2.06
-0.01000-0.48%
After Hours: Apr 25, 7:30 PM EDT
Comments
Loading...
NRX Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:NRXP | Benzinga
NRX Pharmaceuticals Inc has a consensus price target of $28.8 based on the ratings of 5 analysts. The high is $45 issued by Ascendiant Capital on December 2, 2024. The low is $18 issued by BTIG on April 2, 2025. The 3 most-recent analyst ratings were released by BTIG, D. Boral Capital, and D. Boral Capital on April 2, 2025, March 31, 2025, and March 24, 2025, respectively. With an average price target of $26.67 between BTIG, D. Boral Capital, and D. Boral Capital, there's an implied 1194.50% upside for NRX Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BTIG
D. Boral Capital
HC Wainwright & Co.
Ascendiant Capital
EF Hutton
1calculated from analyst ratings
Analyst Ratings for NRX Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | 773.79% | BTIG | Thomas Schrader14% | → $18 | Initiates | → Buy | Get Alert |
| 03/31/2025 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 03/20/2025 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 03/20/2025 | Buy Now | 822.33% | HC Wainwright & Co. | Vernon Bernardino50% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 03/14/2025 | Buy Now | 822.33% | HC Wainwright & Co. | Vernon Bernardino50% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 01/28/2025 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 01/06/2025 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 01/02/2025 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 12/31/2024 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | 2084.47% | Ascendiant Capital | Edward Woo53% | $44 → $45 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 822.33% | HC Wainwright & Co. | Vernon Bernardino50% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 1404.85% | D. Boral Capital | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 1404.85% | EF Hutton | Jason Kolbert44% | $31 → $31 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | 1404.85% | EF Hutton | Jason Kolbert44% | → $31 | Initiates | → Buy | Get Alert |
| 09/12/2024 | Buy Now | 2035.92% | Ascendiant Capital | Edward Woo53% | $43 → $44 | Maintains | Buy | Get Alert |
| 08/05/2024 | Buy Now | 822.33% | HC Wainwright & Co. | Vernon Bernardino50% | $2 → $19 | Maintains | Buy | Get Alert |
| 06/07/2024 | Buy Now | 1987.38% | Ascendiant Capital | Edward Woo53% | $50 → $43 | Maintains | Buy | Get Alert |
| 05/25/2023 | Buy Now | -2.91% | HC Wainwright & Co. | Vernon Bernardino50% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 02/02/2023 | Buy Now | -2.91% | HC Wainwright & Co. | Vernon Bernardino50% | → $20 | Reiterates | → Buy | Get Alert |
| 11/09/2022 | Buy Now | 94.17% | Ascendiant Capital | Edward Woo53% | → $40 | Initiates | → Buy | Get Alert |
| 06/30/2022 | Buy Now | -2.91% | HC Wainwright & Co. | Vernon Bernardino50% | → $20 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for NRX Pharmaceuticals (NRXP) stock?
The latest price target for NRX Pharmaceuticals (NASDAQ:NRXP) was reported by BTIG on April 2, 2025. The analyst firm set a price target for $18.00 expecting NRXP to rise to within 12 months (a possible 773.79% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NRX Pharmaceuticals (NRXP)?
The latest analyst rating for NRX Pharmaceuticals (NASDAQ:NRXP) was provided by BTIG, and NRX Pharmaceuticals initiated their buy rating.
When was the last upgrade for NRX Pharmaceuticals (NRXP)?
There is no last upgrade for NRX Pharmaceuticals
When was the last downgrade for NRX Pharmaceuticals (NRXP)?
There is no last downgrade for NRX Pharmaceuticals.
When is the next analyst rating going to be posted or updated for NRX Pharmaceuticals (NRXP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NRX Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NRX Pharmaceuticals was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating NRX Pharmaceuticals (NRXP) correct?
While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a initiated with a price target of $0.00 to $18.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $2.06, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
